LondonLosing HAT1 sped tumor growth in mouse models.
Median glioblastoma survival has stayed near 15 months since 2005, unchanged by new drugs.
HAT1 loss triggered ALDH2, driving the lipid synthesis a dividing cell needs to build new membrane.
Blood-brain barrier delivery remains untested before any HAT1 drug could reach patients.
Sources: Nature